Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Disagree, and Rich Kaiser/Yes International is no longer tied to PRED. Involved only from the Merle Days.
$1.95 from which brokerage? Schwab, TDA, and many others only show $2.00.
Another note FWIW, the Sagent v. Infusive countersuit as referenced by Hindeburg. They seemed to ignore the final outcome... a settlement of $0.625M on the side of Infusive (Brad).
This is what you can expect when a group writes an "investigative report" with a significant monetary bias.
Age and/or experience will always show over time, especially when things do not go your way.
Agree. I stand behind the company and their response. This is what a legitimate company does.. price then wrong with products, deals, and in the end financials/share price.
That is for the period ending in March of 2019, not June of 2019 which is the reference.
This is important. Sorrentino making the statement holds A LOT of weight.
News: Predictive Technology Group Announces its 11th Consecutive Quarter of Revenue Growth Affirms business strategy and milestones
SALT LAKE CITY, July 15, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces the continuation of consecutive quarter revenue growth for the fiscal 2019 fourth quarter ended June 30, 2019.
“We are proud of our revenue growth, fundamentals and business momentum. We continue to make excellent progress with our strategy to increase sales from our human cell and tissue products, while preparing for the full commercial launch in the coming quarters of our genetic-based endometriosis and fertility diagnostic/prognostic tests,” said Bradley Robinson, CEO of Predictive Technology Group.
“Over the past several months we made significant strides in building a strong infrastructure,” Robinson added. “We strengthened our executive leadership and our board of directors, announced a key global collaboration with Thermo Fisher Scientific to better understand the genetic factors underlying infertility, and presented new genetic data at key industry conferences. We also completed the integration of two DNA laboratories into Predictive Laboratories at a much faster pace than anticipated, and appointed experienced industry veterans to lead this state-of-the-art facility. Additionally, we filed a Form 10 with the United States Securities and Exchange Commission (US SEC) that is effective, making Predictive Technology Group a full reporting 1934 Exchange Act compliant company. And, we submitted an application, which is currently under review, to list Predictive Technology Group’s common stock for trading on The NASDAQ Stock Market.”
The Company expects to report its fourth quarter and fiscal 2019 full year financial results in September 2019.
Predictive is aware that a short-seller recently issued a critical opinion piece regarding the Company in an attempt to manipulate the Company’s stock price. “This opinion piece was produced by anonymous author(s) who admit in the opinion piece that they ‘have taken a really large short position in shares’ of our Company and ‘stand to benefit financially if the stock price declines,’” said John Sorrentino, Chairman of Predictive Technology Group. “As stated in the short-seller opinion’s disclaimers, the anonymous authors refuse to stand behind their allegations – they make ‘no representation, express or implied, as to the accuracy, timeliness, or completeness of [the opinion’s] information. . .’ Given that the short-seller opinion is intended to drive down the price of the Company’s stock and the opinion’s authors have refused to guarantee the accuracy of the ‘information’ the opinion espouses, the Company will not dignify the opinion piece with a point-by-point response. The Company remains focused on developing products that have the potential to improve the quality of life for people throughout the world.”
The Company notes, however, that some of the topics raised in the piece - including the Company’s recent acquisitions - are fully disclosed, in detail, in the Company’s filings with the US SEC. The Company encourages stakeholders to review the detail of these transactions in its US SEC Edgar filings.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contact:
For more information, visit www.predtechgroup.com or contact Investor Relations:
Investor Contact
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
Who ran it up? I'm trying to buy more... c'mon.
Thank you for posting. Good first post!
Reminder... $PRED has some of the best scientists:
Dr. Gregory A. Prince: Scientific Advisory Board.
As a co-founder and CEO of Virion Systems, Inc., Dr. Prince brings pharmaceutical research and development and commercialization expertise to the Scientific Advisory Board team.
After earning doctorate degrees at UCLA (DDS, 1973; PhD, 1975) and serving a post-doctoral fellowship at the National Institutes of Health, Dr. Prince spent four decades in virology research, with a focus on the respiratory syncytial virus (RSV). He pioneered the prevention of RSV disease in high-risk infants, and as co-founder and CEO of Virion Systems, Inc. worked with MedImmune (acquired by AstraZeneca in 2007) to develop Synagis®. AstraZeneca markets Synagis within the United States, while AbbVie markets Synagis in all other regions.
Prince serves on the boards of several non-profit institutions including the National Advisory Council, Dixie State University; the National Advisory Board, J. W. Marriott Library, University of Utah; the National Presidential Advisory Board, Utah Valley University; the Dean's Advisory Council, University of Utah School of Dentistry; and the Board of Governors, Wesley Theological Seminary.
Prince is the author of over 150 scientific publications in the field of infectious diseases, the majority dealing with RSV.
https://www.globenewswire.com/news-release/2018/01/17/1295838/0/en/Predictive-Technology-Group-Appoints-Dr-Gregory-A-Prince-to-Its-Scientific-Advisory-Board.html
https://en.m.wikipedia.org/wiki/Gregory_Prince
That does not account for potential naked shorts, correct? That is where a lot of the large short number speculation is coming from.
Makes you wonder how deep the pockets are, and what we'll see down the road on the investment side..
Let's clear something up, BF Borgers (auditor) is not some small shack behind the CEO's house. They are the 6th largest audit firm for small reporting companies (PRED's current classification).
The Hindenburg article writer selected very specific companies in their large portfolio that sound like poor business ventures. Here are a few others from a cursory glance at recent SEC filings:
Focus Universal : 226M
Mobiquity Technologies: 76M
Helix TCS: 73M
Earth Science Tech: 45M
Fact is, PRED is using a normal and well known audit firm in their current reporting space. Once they get to a higher price range and uplisted exchange, there is no doubt they will select from the top in the next bracket as well.
Please do your own DD, everything in the article mentioned (I will not link to that BS) is easily refuted or makes sense when properly contextualized.
$PRED... check the fundamentals. Leadership speaks for itself, take advantage of the imminent rebound at a minimum and steal-worthy low share price.
$PRED... check the fundamentals. Leadership speaks for itself, take advantage of the imminent rebound at a minimum.
$PRED... check the fundamentals. Leadership speaks for itself, take advantage of the imminent rebound at a minimum.
Will be buying during all of this. The more you research the real story of the company, the more you realize how much of a gift the shorts are giving us. Going to be a very merry Christmas in the BearNaked household.
By far the largest blue chip in my portfolio, never has steered me wrong.
Predicting a very strong next couple years, given future of Xbox (gamepass), holo lens, and other groundbreaking spaces. Expecting a 20% return by Dec of next year.
Hindenburg Investment Research "Hit-Job" CIVIL and CRIMINAL RICO
Still believe it's a $25B company short-term. Why would I sell at any uptick with that upside? I don't have any proprietary charts.. Lol. Still holding all.
Congratulate you on your gains, do hope you sell before we come back. Will make for a good steak dinner! Ha
Date stamp all the way back to your earliest posts, or let's talk about that 3.90 close prediction that was way off last week. Swinging as strong as a random number generator, and you're about to again lower your average. Quit while you're ahead!
You have been right the past week only, before that terrible inaccurate. Lol... I don't look at a couple data points to explain the whole set.
This company was more harshly scrutinized over the past 5 years, than it was as of recent. We vetted this to be anything but a scam multiple times over. The article has nothing but speculation, spins on normal dealings of companies in development stages, and an overall blindness to very large confidence drivers.
95% downside my ass. I do truly hope the company announces litigation, that is all I would like to see as a response. Spend their time focusing on product development and uplist. In the end we'll force a short cover with pure financials if nothing else.
To clarify - the SEC accepted/approved the form 10, not the Nasdaq. The SEC also does not dive into the reasons, more ensuring that the paper trail and detail is accurate and called out correctly. Nasdaq would review more from the second lens of ensuring everything is legitimate.
But yes, there is more than enough confidence/evidence on every front that this company is nothing but legitimate.
And the earth being flat would be obvious to most people that havent had a proper education. It's drama, and you'll see many point to it for a while so they can increase their clicks.
Believe the "short seller fabrication" was a reference to the hit piece, not there being no short sellers present.
Yes, and they know the max fine potential is less than what they'll make by shorting (or lose in a squeeze).
I'm not flooding positive posts, because they wouldn't add value... just redundant. Don't mistake my silence for anything but continued confidence in the company.
At this point we just wait, and we'll end up better for it.
You got it... we'll recover, not expecting CVSI's timeline, but will get there.
Well, this sucks. Grabbing my hard hat, hope we see the light soon! Very much an attack.
Looking like I'll owe Mr. Canuck that steak.
Think we may be agreeing... just semantics - let me know if this doesn't clear up or we've still got a disconnect:
Agree there is a process timeline for both Nasdaq review and the company and that's what I quoted, and the stated average range is not a definite. Yes things can be pushed and often do with no upper limit - not saying there is one nor any red flag from not meeting the average (!!!). But I am just giving documented visibility of the normal case, not the exceptions. These timings only provide a good timing framework, and if anything understand why timing shifts as it does.
Completely agree with the second point.
There is absolutely a timeline being followed and is called out in both their listing guidelines and in their equity rules under section 1010 (1014 specifically, previously quoted).
Let us know if you find something new or language that goes against previously understood references.
In regards to the 45 days, it does include holidays and weekends. Business days are only used when specifically referenced, or the time period is less than 10 days.
http://nasdaq.cchwallstreet.com/NASDAQTools/PlatformViewer.asp?selectednode=chp_1_1_1_1&manual=/nasdaq/main/nasdaq-equityrules/
The past is guaranteed, but the future isn't. If the company did uplist or announce anything more, a sell would have been silly in hindsight.
Again, if your take is to be an investor, doesnt mean a thing. If you're trading and weren't already doing support/resistances, you would have missed out many times over, but are risking a major gap or run.
Not unclear, new (large buyers) will enter in on Nasdaq for many reasons. Just the uplist alone will bring national attention which far from exists today.
And yes, at this point the current investors appear to be near tapped and unable to margin. I can continue to add, and will, but like previously... small (few 1000) chunks at a time.
Playing with fire, see you on the 18th (two weeks).
The Nasdaq application review requires a registered security (spelled out in the provisions), so the company's application review start date would be 6/3 which is the form 10 acceptance.
Not sure what you're arguing.
Not sure what you're referencing, I for one and many others have been posting consistently and are still very positive. Not frustrated or worried... not sure why I would be spamming the Ra Ra Ras. Let it go down, we'll be happy for the cheap shares.
They were not registered as SEC reporting until the form 10 was accepted they previously ended obligations with a 15D. Enough misinformation.
No concern here, let the shorts play and people sell. Only very short-term.